Compare American Express Co (AXP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Express Co vs State Street SPDR S&P Biotech ETF — how do they compare? American Express Co trades at $357.4 (market cap $242.27B), while State Street SPDR S&P Biotech ETF trades at $155.32. The key difference: American Express Co pays a 1.07% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, American Express Co nearer its low. Which is the better fit depends on your goals.
| AXP | XBI | |
|---|---|---|
Market Cap | $242.27B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $384.82 | $164.28 |
52-Week Low | $292.27 | $85.16 |
Dividend Yield | 1.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXP trades at $354.43, up 1.1% today, with a bullish technical signal from moving averages and support at $352. The company reported strong Q1 2026 earnings of $4.28 per share, beating estimates, with revenue reaching $72.23 billion in 2025. Recent news highlights AI investments and a new headquarters, while analyst consensus is a $373.62 price target with 40% buy ratings.
Outlook remains positive driven by revenue growth and premium cardholder expansion, but risks include economic sensitivity and rising debt levels. The stock offers potential upside to consensus targets, supported by institutional confidence and operational momentum, though investors should monitor spending trends and interest rate impacts.
XBI trades at $155.34, down 2.32% on the day, but maintains a bullish technical outlook with strong momentum indicators. The biotech ETF has gained significant attention after a 17% monthly surge, driven by sector rotation and M&A activity. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech's strong performance amid market volatility.
The ETF offers exposure to biotech's resurgence with AI drug discovery and deal momentum as catalysts. However, high volatility and concentrated sector risk require careful position sizing. Current technical strength suggests potential for continued upside if sector momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Express Co
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
